2 registrations that name pramlintide as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 2 registrations
Status
All 2 registrations
RecruitingNCT07506369
Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans
No phase
University Hospital, Gentofte, Copenhagen
About 18 people
Starts Apr 2026 (estimated)
In plain words A study of pramlintide in male participants 18 to 65, run by University Hospital, Gentofte, Copenhagen. It plans to enroll about 18 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists male participants 18 to 65; healthy volunteers accepted. Conditions: Obesity & Overweight.
Male
Age between 18 and 65 years at the time of inclusion
Body mass index 18-27 kg/m2
Fat percentage < 20%
1 more inclusion criterion and the exclusion criteria are on the listing.
The two pancreatic hormones amylin and pancreatic polypeptide (PP) has been linked to satiety and energy metabolism. The goal of this this study is to determine the separate and combined effects of the two hormones on food intake and other exploratory endpoints related to metabolism in healthy humans. The aim of this study is to investigate the interaction between the hormones and obtain insight into the physiology of the hormones. The full summary is on the listing.
Where, as registered
No US site; Denmark (1).
Not yet recruitingNCT07679516
Postprandial Regulation of Bone Perfusion in Healthy Individuals
No phase
University of Copenhagen
About 15 people
Starts Jul 19, 2026 (estimated)
In plain words A study of pramlintide in people 25 to 50, run by University of Copenhagen. It plans to enroll about 15 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 25 to 50; healthy volunteers accepted. Conditions: Healthy Adult Participants; Bone Physiology; Bone Blood Flow Regulation; Peptide Hormones.
Age 25-50 years.
BMI between 18.5-30 kg/m2.
Normal gait.
Premenopausal (if female).
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
isotonic saline infusion; Infusion of GIP(1-42); Infusion of GLP-2(1-33); Infusion of pramlintide
Registered summary
The goal of this clinical trial is to learn whether certain natural hormones - Glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-2, (GLP-2), and amylin - affect blood flow to the bones.